Ads
related to: decitabine dose in aml 1- AML Information
Read More Information About
mIDH1 & Acute Myeloid Leukemia.
- FAQ Page
Additional Questions? Visit Our FAQ
Page For More Information.
- Dosing & Management
Learn About Dosing For R/R mIDH1
Acute Myeloid Leukemia.
- Connect with a Rep
Schedule an Appointment with
A Representative Today
- Access & Resources
HCPs - More Information & Resources
Are Available For You Here.
- Test To Target mIDH1
Learn How To Test To Target IDH1
Mutations In Your Patients With AML
- AML Information
Search results
Results From The WOW.Com Content Network
Decitabine/cedazuridine is indicated for treatment of adults with myelodysplastic syndromes, including previously treated and untreated, de novo and secondary myelodysplastic syndromes with the following French American-British subtypes (refractory anemia, refractory anemia with ringed sideroblasts, refractory anemia with excess blasts, and chronic myelomonocytic leukemia) and intermediate-1 ...
Decitabine (i.e., 5-aza-2′-deoxycytidine), sold under the brand name Dacogen among others, acts as a nucleic acid synthesis inhibitor. [4] It is a medication for the treatment of myelodysplastic syndromes , a class of conditions where certain blood cells are dysfunctional, and for acute myeloid leukemia (AML). [ 5 ]
Venetoclax is also indicated as part of a combination therapy for acute myeloid leukemia (AML). [7] For this purpose it is used with azacitidine, decitabine, or low-dose cytarabine for newly diagnosed adults who are age 75 years or older, or those with other health problems where intensive chemotherapy cannot be used.
Azacitidine is a chemical analogue of the nucleoside cytidine, which is present in DNA and RNA.It is thought to have antineoplastic activity via two mechanisms – at low doses, by inhibiting of DNA methyltransferase, causing hypomethylation of DNA, [16] and at high doses, by its direct cytotoxicity to abnormal hematopoietic cells in the bone marrow through its incorporation into DNA and RNA ...
A hypomethylating agent (or demethylating agent [1]) is a drug that inhibits DNA methylation: the modification of DNA nucleotides by addition of a methyl group.Because DNA methylation affects cellular function through successive generations of cells without changing the underlying DNA sequence, treatment with a hypomethylating agent is considered a type of epigenetic therapy.
High dose: cerebral and cerebellar dysfunction, ocular toxicity, pulmonary toxicity, severe GI ulceration and peripheral neuropathy (rare). Decitabine: IV: DNA methyltransferase inhibitor. Myelodysplastic syndrome, sickle cell anaemia (orphan), acute myeloid leukaemia and chronic myeloid leukaemia.
Ads
related to: decitabine dose in aml 1